Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 6.54 -3.11% -0.21
ATNM closed down 3.11 percent on Monday, March 18, 2024, on 1.32 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Support Bullish -3.11%
Bullish Engulfing Bullish -3.11%
Pocket Pivot Bullish Swing Setup -3.11%
Wide Bands Range Expansion -3.11%
Oversold Stochastic Weakness -3.11%
New Downtrend Bearish 4.31%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 18 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
Down 2 % about 18 hours ago
Down 1% about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Actinium Pharmaceuticals, Inc. Description

Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immunology Natural Sciences Immunotherapy Antibodies Chemical Elements Monoclonal Antibodies Stem Cell Monoclonal Antibody Acute Myeloid Leukemia Platform Technology Transplantation Hematopoietic Stem Cell Cancer Center Actinides Iodine Bismuth Immunotherapy Technology Kettering Cancer Center Memorial Sloan

Is ATNM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Mar 11 Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Feb 28 Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade)
Feb 27 Actinium shares surge on promising data for AML radiotherapy candidate
Feb 26 Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CI...
Feb 23 Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and ...
Jan 2 Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Dec 26 Actinium, Fusion stocks rally on $4.1B RayzeBio takeover deal
Dec 11 Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Dec 11 Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Dec 8 Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
See more ATNM news...

Indicators

Indicator Value
52 Week High 9.55
52 Week Low 4.0
Average Volume 197,493
200-Day Moving Average 6.18
50-Day Moving Average 6.17
20-Day Moving Average 7.38
10-Day Moving Average 7.06
Average True Range 0.53
RSI (14) 46.24
ADX 32.03
+DI 22.57
-DI 22.08
Chandelier Exit (Long, 3 ATRs) 7.20
Chandelier Exit (Short, 3 ATRs) 7.19
Upper Bollinger Bands 8.84
Lower Bollinger Band 5.91
Percent B (%b) 0.21
BandWidth 39.75
MACD Line 0.12
MACD Signal Line 0.35
MACD Histogram -0.2276
Fundamentals Value
Market Cap 181.58 Million
Num Shares 27.8 Million
EPS -1.93
Price-to-Earnings (P/E) Ratio -3.39
Price-to-Sales 266.69
Price-to-Book 3.48
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.49
Resistance 3 (R3) 7.53 7.25 7.33
Resistance 2 (R2) 7.25 7.01 7.23 7.27
Resistance 1 (R1) 6.90 6.86 6.76 6.86 7.22
Pivot Point 6.62 6.62 6.56 6.60 6.62
Support 1 (S1) 6.27 6.38 6.13 6.23 5.86
Support 2 (S2) 5.99 6.23 5.97 5.81
Support 3 (S3) 5.64 5.99 5.75
Support 4 (S4) 5.60